(Q83350170)
English
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin
scientific article published on 01 June 2006
Statements
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis (English)
Gerald Batist
Lyndsay Harris
Nozar Azarnia
Lily Waiyee Lee
Pascual Daza-Ramirez